Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia
This paper outlines the increasing salience of drug “innovation” in the debate for reform of Australia's pharmaceutical policy, particularly change to Australia's price control mechanisms. The pharmaceutical industry has consistently criticised the central role of price control in Australia's pharmaceutical regulatory regime as an impediment to drug innovation and industry growth. Despite ambivalent or contrary evidence on the impact of price control on drug innovation, this criticism, and the appeals for reform it supports, appear to be increasingly influential in directing pharmaceutical policy. This is particularly evident in the implementation of the Australia/United States Free Trade Agreement, which has led to a weakening of the historical process of evidence-based reference pricing in Australia. Should drug innovation come to dominate Australian pharmaceutical policy, there is the potential to precipitate a devaluing of the current public orientation of regulation and diminish equitable access to affordable pharmaceuticals. The manner in which trade policy has effectively undermined a publicly funded pharmaceutical benefits scheme has clear implications for many countries that maintain such programmes.
Keywordsprice control innovation pharmaceutical policy equity
- Sell S . The quest for global governance in intellectual property and public health: structural, discursive and institutional dimensions. Paper Prepared for International Studies Association Conference Montreal, Canada, 17–20 March 2004. Available at http://cyber.law.harvard.edu/blogs/gems/politicshiv/sell.pdf, last accessed 14 April 2007.
- Sweeney K . Review of findings: Australian pharmaceutical pricing in the global context. Working Paper No. 19 (Final) Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004. Available at http://www.cfses.com, last accessed 14 April 2007.
- Salkeld G, Mitchell A, Hill S . Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian Health Policy. Australia: Allen and Unwin; 1998, p. 115–136.Google Scholar
- Hassett KA . Price Controls and the Evolution of Pharmaceutical Markets Draft Paper American Enterprise Institute 2004. Available at https://www.who.int/intellectualproperty/news/en/Submission-Hassett.pdf, accessed 16 October 2006.
- Productivity Commission. International pharmaceutical price differences. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/pbsprices/finalreport/index.html, 2001.
- Productivity Commission. Evaluation of the pharmaceutical industry investment program. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/piip/finalreport/index.html, 2003.
- Richardson J . Priorities of health policy: cost shifting or population health. Working Paper 147. Centre for Health Economics, Monash University, Melbourne 2004. Available at http://www.buseco.monash.edu.au/centres/che/pubs/wp147.PDF.
- Harvey K, Murray M . Medicinal drug policy. In: Gardner H, editor. The Politics of Health, 2nd edition. Melbourne: Churchill Livingstone; 1995, p. 238–283.Google Scholar
- Davey P, Lees M, Aristides M, Ziss S . Report on the Australian System of Pharmaceutical Financing and Delivery. Efficiency and Equity Implications of Public versus Private Funding of Pharmaceuticals, vol. 1. Australia: Medical Technology Assessment Group; 1999.Google Scholar
- Davey P, Lees M, Aristides M . Report on the Australian system of pharmaceutical financing and delivery. Cost-effectiveness of pharmaceuticals, vol. 2 Australia: Medical Technology Assessment Group; 1999.Google Scholar
- Productivity Commission. Impact of advances in medical technology on Australia. Research Report. Melbourne. Available at http://www.pc.gov.au/study/medicaltechnology/finalreport/medicaltechnology.pdf, 2005.
- Calfee JE . Prices, Markets and the Pharmaceutical Revolution. AEI: Washington DC; 2000.Google Scholar
- Danzon PM . Pharmaceutical Price Regulation; National Policies versus Global Interests. Washington, DC: American Enterprise Institute; 1997.Google Scholar
- Sheehan P . Pharmaceuticals and public policy: an assessment of the Productivity Commission Draft Report. A submission to the Productivity Commission. Centre for Strategic Economic Studies, Victoria University of Technology 2003. Available at http://www.cfses.com.
- Schneerman K . The pharmaceuticals industry: prescription for the health and wealth of the nation. Australian Chief Executive, July 2003: 38–40.Google Scholar
- Sheehan P . Pharmaceuticals, health and industry development: strategic issues and options. Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper Series, Working Paper No. 13. Centre for Strategic Economic Studies 2002. Available at http://www.cfses.com.
- Rasmussen B . Innovation and industry structure in the biomedical industry: some preliminary results. Working Paper No. 17 (Final Draft). Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004a. Available at http://www.cfses.com.
- Rasmussen B . Alliance opportunities for AusBiotech. Pharmaceutical Industry Project Working Paper Series, Working Paper No. 23. Centre for Strategic Economic Studies, 2004b. Available at http://www.cfses.com.
- Rasmussen B . Developing the biomedical industries in Canada and Australia: an innovation systems approach. Working Paper No. 24, Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2005. Available at http://www.cfses.com.
- McKelvey M, Orsenigo L . Pharmaceuticals as a sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation) and within the Epris Project 2001. Available at http://www.druid.dk/conferences/winter2002/gallery/orsenigo.PDF.
- Lacetera N, Orsenigo L . Political regimes, technological regimes and innovation in the evolution of the pharmaceutical industry in the USA and in Europe. Paper prepared for the “Conference on Evolutionary Economics”, Johns Hopkins University, Baltimore, 30–31 March 2001. Available at http://www.fgcasal.org/politicafarmaceutica/docs/Nicola_Lacetera_and_Luigi_Orsenigo.PDF.
- McKelvey M, Orsenigo L . Pharmaceuticals as sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation), 2001. Available at http://www.druid.dk/conferences/winter2002/gallery/orsenigo.PDF.
- Love J . Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines, 2003. Available at http://www.cptech.org/ip/health/rnd/evidenceregardingrnd.pdf.
- Wright DJ, Profitability and leakage under the PBS Australian Review of Public Affairs, 2003. Available at http://www.australianreview.net/digest/2003/12/wright.html.
- Grattan M, Stafford A . US drug companies eye Australia. The Age, 29 August 2006.Google Scholar
- Sutherland T . US envoy targets trade issues. The Australian Financial Review, 29 August 2006.Google Scholar
- Mecurio B . The impact of the Australia United States Free Trade Agreement on the provision of health services in Australia. Whittier Law Rev. 2005;26:1051.Google Scholar
- Haynes S . The triumph is in the text: Australia – United States Free Trade Agreement: new opportunities and impacts. Available at http://www.apec.org.au/docs/fta04Haynes.pdf.
- Lokuge B, Faunce TA . Trade disputes and the pharmaceutical benefits scheme: constructive ambiguities, non-violation nullification disputes and the Australia-United States Free Trade Agreement. Working Paper Centre for Governance of Knowledge and Development, 2004. Available at http://cgkd.anu.edu.au/menus/PDFs/TradedisputesandthePharmaceuticalBenefitsScheme.pdf.
- Harvey KJ, Faunce TA, Lokuge B, Drahos P . Will the Australia–United States Free Trade Agreement undermine the pharmaceutical benefits scheme? Med J Aust. 2004;181 (5):256.Google Scholar